Done Medical Leadership and Credentials: An Independent Review

What Is Done and Who Runs Its Medical Operations?

Done (also registered as Done Global Inc.) is a subscription-based telehealth service that markets itself as a fast, low-cost path to ADHD diagnosis and stimulant treatment. Patients pay a monthly fee, complete an online intake questionnaire, and are matched with a clinician for a video or asynchronous visit.

Public documentation of Done's named medical director or chief medical officer is limited. The company's website as of mid-2025 does not prominently list an identified physician executive with verifiable board certifications or published clinical affiliations. That absence is meaningful for consumers evaluating YMYL (Your Money or Your Life) health decisions.

What Credentials Should a Telehealth Medical Director Hold?

A legitimate telehealth platform prescribing Schedule II controlled substances should have, at minimum, a named medical director who holds a current, unrestricted state medical license, DEA registration, and board certification in a relevant specialty, typically psychiatry, family medicine, or internal medicine. The American Telemedicine Association's practice guidelines describe clinical leadership requirements for telehealth organizations delivering controlled substances.

Consumers can verify individual clinician licensure through their state medical board. The Federation of State Medical Boards maintains a consolidated lookup at fsmb.org, though the primary source for license verification is always the issuing state board itself.

Where to Verify Clinician Licenses

Each prescriber on the Done platform must hold a valid, active license in the state where the patient is located. Clinicians prescribing controlled substances also require an active DEA registration number. You can verify a DEA registration at the DEA Diversion Control Division registrant lookup. State board disciplinary histories are public records and searchable through each state's medical board website.

The table below summarizes the verification steps any patient should run before accepting a controlled-substance prescription from any telehealth platform, including Done.

| Verification Step | Resource | What to Look For | |---|---|---| | Clinician state license | State medical board website | Active status, no restrictions | | DEA registration | DEA Diversion Control lookup | Valid registration number | | Platform pharmacy accreditation | LegitScript.com | "Accredited" or "Certified" status | | BBB complaint history | BBB.org | Rating, volume of unresolved complaints | | FDA warning letters | FDA.gov enforcement database | Any action against the platform |

Is Done Legit? Regulatory and Legal Context

The question "is Done legit?" most commonly refers to two distinct concerns: whether the platform is legally authorized to prescribe stimulants, and whether it operates ethically.

On the legal question, Done operates under the same telemedicine-and-controlled-substances framework that covers all U.S. Telehealth prescribers. The Ryan Haight Online Pharmacy Consumer Protection Act requires that a prescriber conduct at least one in-person evaluation before prescribing a controlled substance via the internet, with a telemedicine exception available during federally declared public health emergencies.

The DEA Telemedicine Extension and What It Means

The COVID-19 public health emergency expired in May 2023. The DEA subsequently issued a series of temporary rules extending telemedicine prescribing flexibilities for controlled substances while it works toward a final Special Registration framework. As of July 2025, the DEA's temporary extension remains in effect, meaning clinicians may still prescribe Schedule II stimulants via telemedicine without a prior in-person visit, provided they comply with the DEA's temporary rule requirements. The DEA's proposed special registration rule would require platforms like Done to register separately and comply with additional safeguards. Consumers should monitor the DEA Diversion Control Division for rule updates.

The FDA's guidance on internet pharmacies and the FTC Act's prohibition on deceptive practices also apply to how Done markets its services.

Schedule II Stimulants: The Specific Risk Profile

Done's core product involves prescribing Schedule II controlled substances, primarily amphetamine salts (Adderall, generic mixed amphetamine salts) and methylphenidate compounds. Schedule II is the highest-restriction category for substances with accepted medical use under 21 U.S.C. § 812. The FDA's prescribing information for amphetamine salts carries a boxed warning noting high abuse potential and dependence risk.

The FDA boxed warning for amphetamine states: "Amphetamines have a high potential for abuse. Administration of amphetamines for prolonged periods of time may lead to drug dependence." Any prescriber or platform dispensing these medications carries direct responsibility for appropriate diagnostic evaluation before prescribing.

Done's Complaint Record: BBB, App Stores, and Consumer Reports

Done has accumulated a substantial public complaint record across multiple consumer platforms. The Better Business Bureau profile for Done Global Inc. Lists complaints in categories including billing and collection issues, problems with product or service, and advertising and sales issues. BBB complaint records are publicly searchable and include the company's responses. The pattern across consumer review platforms shows several recurring themes.

Billing and Subscription Disputes

Multiple patient complaints on the BBB and on app store reviews describe difficulty canceling Done subscriptions after deciding to stop using the service. Charges continuing after cancellation requests are among the most frequent complaint types. Under the FTC's Negative Option Rule, subscription services must provide clear, easy cancellation mechanisms. Patients who believe they have been charged improperly after cancellation may file a complaint with the FTC at reportfraud.ftc.gov.

Prescription Delays and Prior Authorization Friction

A second cluster of complaints involves delays in receiving prescriptions or prior authorizations, particularly after pharmacy shortages of generic amphetamine salts that affected the entire market from 2022 onward. The FDA reported ongoing shortages of amphetamine mixed salts on its Drug Shortages database. Some Done patients reported difficulty reaching clinicians when their prescriptions required follow-up or modification during the shortage period.

Customer Service and Response Complaints

A third category of complaints involves difficulty reaching human support. Telehealth platforms with asynchronous or app-mediated workflows create friction when patients need urgent clinical follow-up. A platform prescribing Schedule II controlled substances is expected, under standard of care, to provide timely access to the prescribing clinician for adverse effects, dosing concerns, or emergencies.

The Diagnostic Standard for ADHD: What Done Is Required to Meet

ADHD diagnosis in adults requires more than a questionnaire. The DSM-5-TR criteria require that at least five of nine inattentive or hyperactive-impulsive symptoms be present, that symptoms have persisted for at least 6 months, that they appeared before age 12, and that they cause impairment in two or more settings. Differential diagnosis must exclude mood disorders, anxiety, sleep disorders, and substance use, all of which can mimic ADHD symptoms.

The American Academy of Pediatrics and the American Psychiatric Association both emphasize that self-report symptom scales (such as the Adult ADHD Self-Report Scale, ASRS) are screening tools, not diagnostic instruments. As the American Psychiatric Association's practice guideline notes: "A diagnosis of ADHD requires a comprehensive evaluation, including clinical interview, review of symptom history, and collateral information when available."

Done's intake flow relies heavily on self-reported symptom questionnaires. Whether the subsequent clinician visit provides sufficient depth of evaluation to meet DSM-5-TR criteria is a question patients and clinicians should consider critically.

ADHD Over-Diagnosis and Telehealth-Specific Concerns

A 2023 JAMA Network Open analysis found that telemedicine ADHD visits were significantly more likely than in-person visits to result in a new stimulant prescription, raising questions about the depth of diagnostic evaluation in some telehealth workflows. The study examined insurance claims data and found the association held even after controlling for patient demographics. Patients deserve a diagnostic process that can withstand clinical scrutiny, not just one that converts a screening questionnaire into a Schedule II prescription within minutes.

What a Thorough ADHD Evaluation Includes

A complete adult ADHD evaluation should include a structured clinical interview covering symptom onset (before age 12), duration (at least 6 months), and functional impairment across multiple settings. Clinicians should review prior school records or reports when available, screen for comorbid conditions including anxiety, depression, and substance use disorders, and obtain collateral history from a partner or family member when possible. Cardiovascular history is also relevant given that stimulants raise heart rate and blood pressure; the FDA prescribing information for amphetamine salts lists contraindications including symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, and known hypersensitivity to the drug.

LegitScript Accreditation: What It Means and How to Check Done

LegitScript is an independent certification body that evaluates online pharmacies and telehealth platforms against pharmacy laws and practice standards. LegitScript accreditation (for platforms) and certification (for pharmacies) are voluntary, third-party verifications that a company meets regulatory requirements. The LegitScript database is publicly searchable.

Consumers should search Done Global Inc. In the LegitScript database and verify the current accreditation status before enrolling. A "Not Recommended" or "Rogue" designation from LegitScript is a serious red flag. An absence of listing does not necessarily indicate a problem, as the accreditation program is voluntary, but its presence is a positive signal.

The National Association of Boards of Pharmacy (NABP) operates a similar program called ".pharmacy" domain accreditation for online pharmacies and also publishes a "Not Recommended" list. Checking both databases takes under five minutes and can meaningfully inform a patient's decision.

How Done Compares on Transparency: A Clinical Perspective

Transparency benchmarks for telehealth platforms prescribing controlled substances include named, verifiable medical leadership; publicly listed clinician rosters with license verification links; published prescribing protocols for Schedule II medications; clear informed consent documentation that includes the boxed warning for stimulants; and a documented process for managing adverse events or prescription concerns.

Platforms like Talkiatry, Cerebral (which faced FTC scrutiny in 2023), and Done have all operated in similar cash-pay ADHD telehealth spaces with varying levels of transparency. Cerebral agreed to a consent order with the FTC in October 2023 related to its handling of sensitive health data and subscription practices. The FTC action against Cerebral is instructive because it demonstrates the regulatory risk that accrues to platforms that combine subscription billing with sensitive medical services and limited transparency.

Done has not, as of the publication date of this article, been subject to a published FTC consent order or FDA warning letter. That absence is not a guarantee of compliance; it may reflect regulatory timing as much as conduct.

What Patients and Clinicians Should Ask Before Using Done

Patients considering Done should ask: Who is the specific licensed clinician who will evaluate and prescribe for me? Can I verify their state license and DEA registration? What is the platform's process if I have a side effect at 10 p.m. On a Friday? What happens to my prescription management if Done changes its business model or ceases operations?

Clinicians receiving patients previously treated through Done should request complete records of the diagnostic evaluation, prior treatment history, and the specific stimulant formulation and dose prescribed. Incomplete records are a patient safety concern when managing Schedule II medications.

State Medical Board Oversight of Done Clinicians

Done's prescribers are individually subject to the medical board jurisdiction of each state in which they hold licensure. State boards have authority to investigate complaints about inadequate evaluation before prescribing controlled substances, inappropriate prescribing volume, and failure to follow up with patients on controlled substances.

Patients who believe a Done clinician prescribed without an adequate evaluation may file a complaint with the state medical board where the clinician is licensed. The Federation of State Medical Boards provides a state board directory with direct links to complaint portals for every U.S. Jurisdiction.

Filing a complaint with a state board does not guarantee investigation, but it creates a record that regulators use when identifying patterns across a platform's prescribers. A cluster of similar complaints from patients of the same telehealth platform can trigger a coordinated multi-state review.

Original HealthRX Assessment Framework for ADHD Telehealth Platforms

The HealthRX medical team evaluates ADHD telehealth platforms across five dimensions: diagnostic rigor, prescriber transparency, regulatory compliance posture, patient safety infrastructure, and billing practice integrity. Done scores as follows based on publicly available information as of July 2025:

| Dimension | Observable Signal | Assessment | |---|---|---| | Diagnostic rigor | Intake relies heavily on self-report; clinician visit time not publicly specified | Moderate concern | | Prescriber transparency | Named medical director not prominently disclosed; license verification not linked from platform | Elevated concern | | Regulatory compliance | Operating under DEA temporary extension; no published FTC or FDA action as of July 2025 | Neutral; monitor | | Patient safety infrastructure | Complaints about difficulty reaching clinicians for follow-up | Moderate concern | | Billing practice integrity | BBB complaints include post-cancellation charges; subscription model with limited friction | Elevated concern |

This framework is designed for consumer and clinician reference. Each dimension should be re-evaluated as new regulatory actions or company disclosures become available.

Practical Guidance for Patients Considering or Currently Using Done

If you are considering Done, request the full name and license number of the clinician who will be assigned to you before completing payment. Verify that license at your state medical board website and confirm the clinician's DEA registration at the DEA Diversion Control lookup. Read the cancellation terms before entering your payment details, and document the cancellation process in writing if you decide to stop.

If you are currently a Done patient receiving stimulant treatment and are satisfied with your care, maintain records of your diagnosis documentation, your current dose, and the clinician's contact information. Stimulant continuity matters: abrupt loss of access to a Schedule II prescription is a clinical problem, not just an inconvenience.

Patients experiencing cardiovascular symptoms (racing heart, chest pain, elevated blood pressure) on stimulants should contact emergency services or their primary care physician immediately. The FDA's MedWatch program accepts adverse event reports from patients directly at 1-800-FDA-1088.